Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis
Omoniyi J. Adedokun(Western University), William J. Sandborn(University of San Diego), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Rupert W. Leong(The University of Sydney), Tadakazu Hisamatsu(Kyorin University), Gert Van Assche(KU Leuven), Silvio Danese(IRCCS Ospedale San Raffaele), Colleen Marano(Johnson & Johnson (United States)), Zhenhua Xu(Hebei Medical University), Philippe Szapary(Cedars-Sinai Medical Center), Chris O’Brien(Neurocrine Biosciences (United States)), Jewel Johanns(Johnson & Johnson (United States)), Hongyan Zhang(Northwest A&F University), María T. Abreu(Icahn School of Medicine at Mount Sinai)
Cited by 107
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k